1. Summary Information
|
|
|
Country |
|
|
Company Name |
BDR
PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED |
Principal Name 1 |
Mr. Raheel Dharmesh Shah |
|
Status |
Good |
Principal Name 2 |
Mr. Suresh Chhabildas Shah |
|
|
|
Registration # |
11-137329 |
|
Street Address |
407 -408, Sharda
Chambers,, New Marine Lines, Mumbai-400020, |
||
|
Established Date |
24.09.2002 |
SIC Code |
-- |
|
Telephone# |
91-22-40560560 |
Business Style 1 |
Manufacturer |
|
Fax # |
91-22-40560555 |
Business Style 2 |
Trader |
|
Homepage |
Not Available |
Product Name 1 |
Pharmaceutical Raw Material |
|
# of employees |
35
(Approximately) |
Product Name 2 |
-- |
|
Paid up capital |
Rs.5.000
Millions |
Product Name 3 |
-- |
|
Shareholders |
Directors or
relatives of Directors – 100% |
Banking |
ABN
Amro Bank N.V |
|
Public Limited Corp. |
NO |
Business Period |
11 Years |
|
IPO |
NO |
International Ins. |
- |
|
Public |
NO |
Rating |
|
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
Associates |
-- |
Sunshine Organics Private Limited |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2007 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
894,963,000 |
Current Liabilities |
743,262,000 |
|
Inventories |
141,274,000 |
Long-term Liabilities |
26,380,000 |
|
Fixed Assets |
19,091,000 |
Other Liabilities |
90,003,000 |
|
Deferred Assets |
0,000 |
Total Liabilities |
859,645,000 |
|
Invest& other Assets |
113,872,000 |
Retained Earnings |
304,555,000 |
|
|
|
Net Worth |
309,555,000 |
|
Total Assets |
1,169,200,000 |
Total Liab. & Equity |
1,169,200,000 |
|
Total Assets (Previous Year) |
965,876,000 |
|
|
|
P/L Statement as of |
31.03.2007 |
(Unit: Indian Rs.) |
|
|
Sales |
1,536,945,000 |
Net Profit |
94,385,000 |
|
Sales(Previous yr) |
1,222,765,000 |
Net Profit(Prev.yr) |
48,115,000 |
MIRA
INFORM REPORT
|
Report Date : |
06.06.2013 |
IDENTIFICATION DETAILS
|
Name : |
BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
407 -408, Sharda Chambers,, New Marine Lines, Mumbai-400020, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2012 |
|
|
|
|
Date of
Incorporation : |
24.09.2002 |
|
|
|
|
Com. Reg. No.: |
11-137329 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 5.000 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24230MH2002PTC137329 |
|
|
|
|
PAN No.: [Permanent Account No.] |
AABCB9286B |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer and Trader of Pharmaceutical Raw Material, they do
Manufacturing through Job Work. |
|
|
|
|
No. of Employees
: |
35 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (51) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 1238000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track.
Financial position of the company appears to be sound. Directors are reported
to be experienced and respectable businessmen. Trade relations are reported
as fair. Business is active. Payments are reported to be regular and as per
commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
LOCATIONS
|
Registered Office / Corporate Head Quarter : |
407 -408, Sharda Chambers,, New Marine Lines, Mumbai-400020, |
|
Tel. No.: |
91-22-40560560 |
|
Fax No.: |
91-22-40560555 |
|
E-Mail : |
|
|
|
|
|
Regional Office : |
LOCATED AT: v
Ahmedabad |
|
|
|
|
Factory / Sites : |
ALSO LOCATED AT: v
v
|
DIRECTORS
As on 30.09.2012
|
Name : |
Mr. Raheel Dharmesh Shah |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
2301-A,2302-B, |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
20.01.1990 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
27.07.2011 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
03582861 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Dharmesh Mahendra Shah |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
2301, |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
15.03.1966 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Qualification : |
Chemical Engineer |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
24.09.2002 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00452961 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Vijay Chhabildas Shah |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
501, Panchsheel, 5th Floor, |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
19.02.1945 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
05.01.2004 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00453308 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other
Directorship:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Tejash Vijay Shah |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
Room No. A 29, B 51-52, |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
11.08.1978 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
16.01.2008 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
01862033 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MAJOR SHAREHOLDERS
As on 30.09.2012
|
Names of Shareholders |
|
No. of Shares |
|
Dharmesh Mahendra Shah |
|
4900 |
|
Binita Dharmesh Shah |
|
347900 |
|
M Sharmishta Shah |
|
147000 |
|
Vijay Chabildas Shah |
|
100 |
|
Suresh Chabildas Shah |
|
100 |
|
Total |
|
500000 |
Equity Share Break up (Percentage of Total Equity)
As on 30.09.2012
|
Category |
Percentage |
|
Directors or relatives of Directors |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Trader of Pharmaceutical Raw Material, they do
Manufacturing through Job Work. |
GENERAL INFORMATION
|
No. of Employees : |
35 (Approximately) |
||||||||||||
|
|
|
||||||||||||
|
Bankers : |
v
ABN Amro Bank N.V., 7th Floor,
Sakhar Bhavan, Nariman Point, Mumbai – 400 021, |
||||||||||||
|
|
|
||||||||||||
|
Facilities : |
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Lalit Mehta and Company Chartered Accountants |
|
Address : |
101, Apollo Arcade, R.K. Singh Marg, Off P.P. Road, Near Sona Udyog, Andheri
(East), Mumbai – 400069, Maharashtra, India |
|
PAN No.: |
AABPM6331K |
|
|
|
|
Associates : |
v
Sunshine Organics Private Limited (CIN No: U24110MH1988PTC048981) v
BDR Life Sciences Private Limited (CIN No:
U24230GJ1993PTC020258) v
Innova Life Sciences Private Limited (CIN No: U24230MH2003PTC143625) v
Virdev Intermediates Private Limited (CIN No: U24230GJ1994PTC021189) v
Mepromax Life Sciences Private Limited (CIN No: U24231GJ2005PTC021189) v
B K Life Sciences Private Limited (CIN No: U24239MH2006PTC164688) v
Mepro Laboratories v
Mepro Pharmaceuticals Private Limited v
M J Chempharm Private Limited |
CAPITAL STRUCTURE
As on 31.03.2012
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1000000 |
Equity Shares |
Rs.10/- each |
Rs. 10.000 Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
500000 |
Equity Shares |
Rs.10/- each |
Rs. 5.000 Millions |
FINANCIAL DATA
[all figures are in
Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
5.000 |
5.000 |
5.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
304.555 |
218.886 |
171.109 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
309.555 |
223.886 |
176.109 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1.403 |
0.000 |
0.000 |
|
|
2] Unsecured Loans |
24.977 |
23.410 |
9.596 |
|
|
TOTAL BORROWING |
26.380 |
23.410 |
9.596 |
|
|
DEFERRED TAX LIABILITIES |
0.503 |
0.291 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
336.438 |
247.587 |
185.705 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
19.091 |
9.680 |
6.036 |
|
|
Capital work-in-progress |
38.906 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
74.966 |
74.966 |
74.775 |
|
|
DEFERRED TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
141.274
|
84.225 |
116.864 |
|
|
Sundry Debtors |
450.606
|
444.018 |
427.039 |
|
|
Cash & Bank Balances |
343.438
|
279.495 |
157.096 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
100.919
|
73.492 |
42.076 |
|
Total
Current Assets |
1036.237
|
881.230 |
743.075 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
0.000
|
0.000 |
599.452 |
|
|
Other Current Liabilities |
743.262
|
659.589 |
4.920 |
|
|
Provisions |
89.500
|
58.700 |
33.809 |
|
Total
Current Liabilities |
832.762
|
718.289 |
638.181 |
|
|
Net Current Assets |
203.475
|
162.941 |
104.894 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
336.438 |
247.587 |
185.705 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
1536.945 |
1222.765 |
915.159 |
|
|
|
Other Income |
46.204 |
20.095 |
22.741 |
|
|
|
TOTAL |
1583.149 |
1242.860 |
937.900 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Administrative Expenses |
|
|
|
|
|
|
Advertising Expenses |
|
|
|
|
|
|
TOTAL |
1442.975 |
1169.791 |
875.250 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION |
(Including |
(Including |
62.650 |
|
|
|
|
Financial |
Financial |
|
|
|
Less |
FINANCIAL
EXPENSES |
Expenses and |
Expenses and |
6.367 |
|
|
|
|
Depreciation) |
Depreciation) |
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION |
|
|
56.283 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION |
|
|
0.733 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER DEPRECIATION
BUT BEFORE TAX |
140.174 |
73.069 |
55.550 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
45.789 |
24.954 |
22.582 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
94.385 |
48.115 |
32.968 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Transfer to General Reserve |
50.000 |
0.000 |
N.A |
|
|
|
Dividend |
7.500 |
0.000 |
N.A |
|
|
|
Tax on Dividend |
1.216 |
0.000 |
N.A |
|
|
BALANCE CARRIED
TO THE B/S |
35.669 |
48.115 |
N.A |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
683.822 |
640.772 |
488.403 |
|
|
TOTAL EARNINGS |
683.822 |
640.772 |
488.403 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
188.77 |
96.23 |
65.94 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2012 |
31.03.2011 |
31.03.2010 |
|
PAT / Total Income |
(%) |
5.96 |
3.87 |
3.52 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
9.12 |
5.98 |
6.07 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
13.28 |
8.20 |
7.42 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.45 |
0.33 |
0.32 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt /Networth) |
|
0.09 |
0.10 |
0.05 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.24 |
1.23 |
1.16 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
Yes |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact
person |
No |
|
11] |
Turnover of firm for last
three years |
Yes |
|
12] |
Profitability for last
three years |
Yes |
|
13] |
Reasons for variation
<> 20% |
-- |
|
14] |
Estimation for coming
financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister
concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details
(if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm
/ promoter involved in |
--- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking
account |
-- |
|
26] |
Buyer visit details |
--- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if
applicable |
Yes |
|
29] |
Last accounts filed at
ROC |
Yes |
|
30] |
Major Shareholders, if
available |
Yes |
|
31] |
Date of Birth of
Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director,
if available |
No |
|
33] |
Voter ID No of
Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating,
if available |
No |
UNSECURED LOAN
|
Particulars |
31.03.2012 (Rs.
in Millions) |
31.03.2011 (Rs.
in Millions) |
|
Unsecured
Borrowings |
|
|
|
Loans and advances from related parties |
24.977 |
23.410 |
|
Total |
24.977 |
23.410 |
WEBSITE DETAILS
PRESS RELEASES
BDR PHARMA
SEEKS LICENCE TO SELL VERSION OF BRISTOL-MYERS SQUIBB CANCER DRUG
18
MARCH 2013
BDR is seeking
permission to sell a generic version of Bristol-Myers Squibb’s cancer drug,
dasatinib
Mumbai: India’s BDR
Pharmaceuticals International Private Limited has applied to the Indian patents
office, seeking permission to sell a generic version of Bristol-Myers Squibb
Co.’s cancer drug, dasatinib, through a so-called compulsory licence mechanism,
a BDR executive said on Monday.
Under a global
Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement,
countries can issue compulsory licences for certain drugs that are deemed
unaffordable to a large section of their populations.
Early this month,
Bayer AG lost an appeal challenging the first-ever compulsory licence issued by
India which allowed Natco Pharma to sell a version of the German drugmaker’s
cancer treatment Nexavar.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No exist to suggest that subject is or was
the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 56.42 |
|
|
1 |
Rs. 86.54 |
|
Euro |
1 |
Rs. 73.86 |
INFORMATION DETAILS
|
Report Prepared
by : |
KVT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER |
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
TOTAL |
|
51 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NB |
NEW BUSINESS |
||
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.